Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Imago BioSciences, founded in 2012 and headquartered in Redwood City, California, is a biotechnology company specializing in the development of drugs for managing proliferative diseases of the bone marrow. The company's primary focus is on inhibitors of the enzyme lysine-specific demethylase 1 (LSD1), which are designed to regulate the growth and development of bone marrow cells. These inhibitors are currently being studied in various clinical trials, showcasing Imago BioSciences' commitment to advancing medical research in this field.
Since its inception, Imago BioSciences has successfully raised a total of $160.5 million in funding, demonstrating significant investor interest in its innovative approach to treating bone marrow disorders. This substantial financial backing has likely contributed to the company's ability to progress its research and development efforts.
It's important to note that in January 2023, Imago BioSciences was acquired by Merck & Co., a major pharmaceutical company. This acquisition has significantly altered the company's trajectory and future prospects. As a result of this acquisition, the likelihood of an initial public offering (IPO) for Imago BioSciences is no longer applicable, as the company is now part of a larger, publicly-traded entity.
For investors interested in gaining exposure to Imago BioSciences' work, the most direct route would be through Merck & Co.'s publicly traded stock. However, it's crucial for potential investors to conduct thorough research and consider seeking professional financial advice before making any investment decisions.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Imago BioSciences' IPO prospects remain uncertain, investors eager to explore opportunities in the biotechnology sector don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotech industry, including companies like Imago BioSciences, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from their growth and innovation before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
